(19)
(11) EP 3 957 234 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
01.01.2025 Bulletin 2025/01

(45) Mention of the grant of the patent:
27.11.2024 Bulletin 2024/48

(21) Application number: 21201217.3

(22) Date of filing: 31.01.2017
(51) International Patent Classification (IPC): 
A61B 5/00(2006.01)
A61B 5/026(2006.01)
A61B 5/01(2006.01)
A61N 1/36(2006.01)
G16H 20/40(2018.01)
G16H 50/20(2018.01)
 A61B 5/0215(2006.01)
A61B 5/053(2021.01)
A61B 5/20(2006.01)
G16H 20/30(2018.01)
G16H 40/63(2018.01)
(52) Cooperative Patent Classification (CPC):
A61B 5/0084; A61B 5/0215; A61B 5/026; A61B 5/053; A61B 5/201; A61B 5/4833; A61N 1/36114; A61N 1/36; G16H 40/63; G16H 50/20; G16H 20/40; A61B 5/01; A61N 1/3606; G16H 20/30

(54)

SYSTEM FOR MONITORING AND EVALUATING NEUROMODULATION THERAPY

SYSTEM ZUR ÜBERWACHUNG UND BEURTEILUNG EINER NERVENMODULATIONSTHERAPIE

SYSTÈME DE SURVEILLANCE ET D'ÉVALUATION DE THÉRAPIE PAR NEUROMODULATION

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 01.02.2016 US 201662289739 P
07.06.2016 US 201662346710 P

(43) Date of publication of application:
23.02.2022 Bulletin 2022/08

(60) Divisional application:
24214262.8

(62) Application number of the earlier application in accordance with Art. 76 EPC:
17704643.0 / 3410923

(73) Proprietor: Medtronic Ireland Manufacturing Unlimited Company
Dublin 2, D02 T380 (IE)

(72) Inventors:
  • TRUDEL, Julia
    Santa Rosa (US)
  • HETTRICK, Douglas
    Santa Rosa (US)

(74) Representative: Zimmermann & Partner Patentanwälte mbB 
Postfach 330 920
80069 München
80069 München (DE)


(56) References cited: : 
WO-A2-2014/160832
US-A1- 2014 249 520
 US-A1- 2011 112 400
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).